biologic therapy – Medxy AI

Early Biologic Initiation in Severe Asthma: Enhancing Remission and Clinical Outcomes from Global Real-World Cohorts

By MedXY 09/16/2026

Earlier initiation of biologic therapies in severe asthma improves clinical remission rates, reduces exacerbations, preserves lung function, and decreases corticosteroid dependence, supporting a shift from reserving to preserving treatment paradigms.

news Ophthalmology Rheumatology

Comparing Long-Term Systemic Risks of Biologic Versus Conventional Therapy in Non-Infectious Uveitis

By MedXY 07/11/2026

A multicenter retrospective study evaluates five-year risks of systemic complications in non-infectious uveitis patients receiving biologic versus conventional therapies, highlighting infection and cytopenia risks with biologics but comparable overall safety to conventional immunomodulators.

Clinical Updates news Pathology & Lab Medicine Public Health Specialties

Is Single-Test Tuberculosis Screening Adequate Before Initiating Biologic Therapy?

By MedXY 09/25/2025

A 20-year cohort study indicates that using QuantiFERON-TB Gold alone for TB screening before biologic therapy effectively reduces TB infection diagnoses and preventive treatments without increasing active TB risk, questioning the need for dual testing or routine retesting.

Allergy & Immunology Clinical Updates Dermatology news Orthopedics Specialties

Combination Targeted Therapy in Psoriatic Arthritis: Evaluating Infection Risks and Usage Patterns

By MedXY 09/03/2025

This article evaluates the prevalence and infection risks associated with combination targeted therapies in adults with psoriatic arthritis, revealing no significant increase in serious or opportunistic infections compared to standard therapy.

Clinical Updates Gastroenterology news Specialties

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.